Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Overcoming immune checkpoint inhibitor resistance using oncolytic viruses

FY 2023-24

Summary
Melanoma is the deadliest form of skin cancer. Prior to 2010, very few people survived melanoma when it spread to distant parts of the body. However, the research community developed therapies that boost your immune system to combat this cancer. While this initial immunotherapy leads to cures for some patients, it doesn't work for everyone. Some individuals don't respond because immune cells can't access the cancer or because the cancer cells have adapted to hide from the immune system. My research is focused on a novel strategy that uses a modified virus that can specifically kill cancer cells while leaving normal cells unharmed. When the cancer cells are killed, they release factors that attract and alert the immune system to the tumor. Thus, we hypothesize that using these viruses will make the initial immunotherapy more effective due to the augmented immune response. To date, one promising virus therapy has been tested in clinical trials, but it was shown to not be very effective. Our lab has preliminary results showing that another type of virus is much more effective than the previously studied one. My project aims to elucidate the reasons why this new virus is more efficient at killing cancer cells and test if it makes the initial immunotherapy more effective. Specifically, we will focus on a protein that helps the immune system recognize and attack cancer cells. We will use different techniques to determine how this virus results in an increase of those proteins in melanoma. Finally, we will use mice to test if combining this virus with the initial immunotherapy can work better in fighting melanoma. My research in this proposal will push this virus one step closer to being in the clinic to help melanoma patients who are not responding to regular immune therapy.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506057
Name
Ghaleb Louis
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Overcoming immune checkpoint inhibitor resistance using oncolytic viruses
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Combination Therapy; Cutaneous Melanoma; Hla-1 Regulation; Imaging Mass Cytometry; Immune Checkpoint Inhibitor Resistance; Immunotherapy; Mouse Models; Oncolytic Viruses; Tumor Immune Infiltration; Tumor Immune Microenvironment
Abstract
Melanoma is the deadliest form of skin cancer. Prior to 2010, very few people survived melanoma when it spread to distant parts of the body. However, the research community developed therapies that boost your immune system to combat this cancer. While this initial immunotherapy leads to cures for some patients, it doesn't work for everyone. Some individuals don't respond because immune cells can't access the cancer or because the cancer cells have adapted to hide from the immune system. My research is focused on a novel strategy that uses a modified virus that can specifically kill cancer cells while leaving normal cells unharmed. When the cancer cells are killed, they release factors that attract and alert the immune system to the tumor. Thus, we hypothesize that using these viruses will make the initial immunotherapy more effective due to the augmented immune response. To date, one promising virus therapy has been tested in clinical trials, but it was shown to not be very effective. Our lab has preliminary results showing that another type of virus is much more effective than the previously studied one. My project aims to elucidate the reasons why this new virus is more efficient at killing cancer cells and test if it makes the initial immunotherapy more effective. Specifically, we will focus on a protein that helps the immune system recognize and attack cancer cells. We will use different techniques to determine how this virus results in an increase of those proteins in melanoma. Finally, we will use mice to test if combining this virus with the initial immunotherapy can work better in fighting melanoma. My research in this proposal will push this virus one step closer to being in the clinic to help melanoma patients who are not responding to regular immune therapy.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ghaleb, Louis
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~